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Abstract
Adjuvant treatment for early breast cancer is an evolving field.
Since the advent of the initial cyclophosphamide, methotrexate and
5-fluorouracil (CMF) regimens, which reduced risk for recurrence
and death, anthracyclines and subsequently taxanes were added
to the cytotoxic armamentarium for use sequentially or in
combination in the adjuvant setting. The efficacy and toxicity of
each chemotherapy regimen must be viewed within the context of
host co-morbidities and the specific biologic phenotype of the
tumor. In the era of mammographic screening, small, node-negative
breast cancer is the most frequent presentation of the disease.
Patient selection for adjuvant chemotherapy has become a key
issue. Traditional prognostic factors continue to be of value in
determining the risk for relapse, but new and sophisticated
genomic tools (such as Oncotype Dx® and Mammaprint®) are now
available and may improve our ability to select patients. For those
patients who do require adjuvant chemotherapy, the ‘one size fits
all’ paradigm should never again feature in the treatment of early
breast cancer, following the important insights yielded by
biomarker research to identify those who will benefit the most from
a particular drug. In this review we focus on some of the current
controversies and potential future steps in adjuvant chemotherapy
for treatment of early breast cancer.
Introduction
Adjuvant systemic therapies were originally developed in an
attempt to eradicate residual micrometastatic disease imme-
diately after local control, in order to reduce the risk for
cancer recurrence and death. From 10% to 30% of lymph
node-negative breast cancer patients and 35% to 90% of
lymph node-positive patients will eventually relapse with local
therapy alone, because of occult micrometastatic disease [1].
Randomized clinical trials (discussed below) have identified
survival benefits from adjuvant therapy, with estimated
reductions in the annual odds of death ranging from 8% to
28%. These benefits are maintained in patients outside the
controlled conditions of clinical trials and have contributed,
alongside screening programs, to an overall reduction in breast
cancer mortality between 1975 and 2000 [2].
During the late 1960s the earliest clinical trials in the field
began to evaluate the biologic concept of adjuvant chemo-
therapy in node-positive breast cancer, determining the effects
of various chemotherapy regimens compared to observation
after surgery  to remove the primary tumor [3]. These trials
clearly demonstrated benefit from adjuvant chemotherapy in
the subgroup of patients at high risk for recurrence [4,5].
Chemotherapy combinations including cyclophosphamide,
methotrexate, and 5-fluorouracil (CMF) have exhibited long-
term effectiveness in women with node-positive breast cancer
[6]. CMF-like regimens were able to reduce the annual odds
of recurrence and death in operable breast cancer patients by
24% (± 3%) and 14% (± 4%), respectively [7].
Subsequently, during the late 1970s and early 1980s,
anthracycline-containing combinations were tested in pros-
pective randomized adjuvant trials. Overall, the anthracycline
regimens (5-fluorouracil, doxorubicin, and cyclophosphamide
[FAC]; 5-fluorouracil, epirubicin, and cyclophosphamide [FEC];
and doxorubicin and cyclophosphamide [AC], among others)
are associated with reductions in the risk for recurrence of
11.2% (2P < 0.0001) and in the risk for death of 16%
(2P < 0.00001), compared with CMF. Therefore, in absolute
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terms, the benefit is about 3% at 5 years and 4% at 10 years
[8,9]. The National Surgical Adjuvant Breast and Bowel
Project (NSABP) group explored the differences between
anthracycline and CMF regimens in two clinical trials, namely
NSABP B-15 and B-23, showing that four cycles of AC were
similar in terms of disease-free survival (DFS) and overall
survival (OS) to six cycles of classical CMF [10,11]. Other
randomized studies and a meta-analysis clearly demonstrated
that six cycles of an anthracycline-containing combination
(FAC; FEC; cyclophosphamide, doxorubicin, and 5-fluorour-
acil; and cyclophosphamide, epirubicin, and 5-fluorouracil
[CEF]) were superior to six cycles of CMF [7,8,12]. The
optimal duration of the adjuvant therapy was also addressed
in a French study (FASG-01) [13], which demonstrated that
six cycles of adjuvant FEC were superior to three cycles of
the same regimen in patients with operable breast cancer.
Based on this growing body of evidence, during the 1990s
consensus emerged that six cycles of a three-drug anthra-
cycline-containing combination was the optimal adjuvant
treatment for node-positive operable breast cancer, although
the use of four-cycle AC and six-cycle CMF remained
common practice in many institutions.
More recently, the taxanes have been added to the adjuvant
armamentarium and are broadly used. In this review we
address current prospects of adjuvant therapy, focusing on
the advances in chemotherapy with taxanes and on treatment
individualization; we also give attention to likely future
developments involving taxanes intended to improve further
outcomes in early-stage breast cancer.
Taxanes as adjuvant therapy for breast cancer
The taxanes paclitaxel and docetaxel have a partial lack of
cross-resistance with anthracyclines and were established in
the 1990s as part of the standard treatment for metastatic
breast cancer. Testing of these agents in the adjuvant setting
was therefore also begun at that time.
Several phase III clinical trials have evaluated taxanes in the
adjuvant setting. There are two generations of taxane clinical
trials. In first-generation trials, a taxane-containing combina-
tion was compared with an anthracycline, nontaxane combi-
nation. In the second generation of trials, initiated once the
taxanes became regarded as the ‘gold standard’, taxanes
were included in all comparator arms.
In the first-generation trials (Tables 1 and 2) taxanes were
added to conventional adjuvant anthracycline regimens, and
were given either sequentially after the anthracyclines or
concurrently in combination with them.
First-generation paclitaxel-containing regimens
The trials discussed here are summarized in Table 1.
The first reported taxane study, the 9344-INT 08 trial [14],
was conducted by the Cancer and Leukemia Group B
(CALGB). Conducted in pre- and postmenopausal women
with node-positive breast cancer, the study aimed to
determine whether the benefits of four cycles of conventional
AC could be improved upon either by doxorubicin dose
escalation or by adding paclitaxel. A 3 × 2 factorial design
was used to address both questions in one trial. Patients
were randomly assigned to receive doxorubicin at one of
three different dosages (60, 75, or 90 mg/m2) in combination
with a fixed dose of cyclophosphamide (600 mg/m2), and
then to receive or not receive four courses of paclitaxel
(175 mg/m2  every 3 weeks). After a median follow up of
69 months, no significant reduction in relation to doxorubicin
dose was identified in the hazard of recurrence or of death.
However, the addition of paclitaxel to AC led to a 17%
reduction in the risk for recurrence (P = 0.0023) and up to an
18% reduction in the risk for death (P = 0.0064). The main
concern with these data is that the superiority of the taxane-
containing regimen could partly be attributed to the more
protracted therapy in this arm (3 versus 6 months), as
opposed to a direct effect of the taxane therapy.
With a very similar design, the NSABP B-28 trial [15] added
four cycles of paclitaxel at a higher dose (225 mg/m2 every
3 weeks) to four cycles of AC (60/600 mg/m2) in a sequential
schedule, and administered adjuvant tamoxifen to all hormone
receptor-positive patients and those older than 50 years,
concurrent with chemotherapy. The addition of paclitaxel
conferred a reduction in the risk for recurrence of 17%
(P = 0.006) over that in patients treated with four cycles of
AC. Analysis of OS, however, did not reveal any statistically
significant differences between arms.
On the European side, the Grupo Español para la
Investigación del Cáncer de Mama (GEICAM) recently
reported the results of the 9906 trial [16], which had a
median follow-up period of 66 months. Patients with node-
positive operable breast cancer were randomized after
surgery to receive six cycles of FEC (fluorouracil 600 mg/m2,
epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 on
day 1 every 3 weeks) or four cycles of the same FEC regimen
followed by 8 weeks of administration of paclitaxel (100 mg/m2
per week). Therefore, the duration of adjuvant treatment in
both arms was very similar. After adjustment for other
variables, FEC plus paclitaxel significantly reduced the risk for
relapse by 23% compared with FEC, and the difference in
DFS between the two arms was related to the greater
number of distant breast cancer relapses in the FEC group.
The analysis of OS identified a trend in favor of the paclitaxel
arm, but the difference was not statistically significant at this
point in the follow up (P = 0.109).
The Hellenic Cooperative Oncology Group trial HE 10/97
[17] compared three cycles of epirubicin (110 mg/m2)
followed by three cycles of paclitaxel (250 mg/m2) and three
cycles of intensified CMF (cyclophosphamide 840 mg/m2,
methotrexate 57 mg/m2, and 5-fluorouracil 840 mg/m2) versusAvailable online http://breast-cancer-research.com/content/11/2/204
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.four cycles of epirubicin every 2 weeks followed by four
cycles of intensified CMF. The study identified a trend toward
better survival in the taxane-containing arms, albeit without
statistical significance. However, the study was under-
powered to show small but clinically relevant differences.
More recently other two clinical trials have been reported in
abstract form. The National Cancer Institute of Canada
Clinical Trials Group MA.21 study, reported by Burnell and
coworkers [18], tested the hypothesis that the addition of
3 months of paclitaxel after dose-dense epirubicin and cyclo-
phosphamide (EC) chemotherapy would be superior to CEF
alone or AC followed by paclitaxel. AC followed by paclitaxel,
although less toxic, was inferior to the other arms in terms of
recurrence-free survival, but it was still too early to detect any
differences between CEF and dose-dense EC plus paclitaxel.
The most recently presented trial is a phase III study conducted
by the Gruppo Oncologico Nord Ovest and Mammella
Intergruppo, namely the GONO-MIG-5 study [19]. The study
compared CEF (cyclophosphamide 600 mg/m2, epirubicin
60 mg/m2, and 5-fluorouracil 600 mg/m2 given every 3 weeks
for six cycles) versus EP (epirubicin 90 mg/m2 and paclitaxel
175 mg/m2 3-hour infusion given every 3 weeks for four cycles).
No significant differences in DFS or OS were observed.
First-generation docetaxel-containing regimens
The trials discussed here are summarized in Table 2.
Chronologically, the first report of docetaxel administered
concurrently with anthracyclines comes from the Breast
Cancer International Research Group (BCIRG)-001, in the
form of their TAX316 trial [20]. This study randomly assigned
women with node-positive breast cancer to six cycles of TAC
(docetaxel 75 mg/m2, doxorubicin 50 mg/m2, and cyclophos-
phamide 500 mg/m2) or FAC (fluorouracil 500 mg/m2,
doxorubicin 50 mg/m2, and cyclophosphamide 500 mg/m2)
every 3 weeks. TAC was associated with a statistically
significant reduction in the risk for relapse and death (28%
and 30%, respectively) relative to FAC. The reduction in the
risk for relapse did not appear to be driven by nodal status or
by hormone receptor or human epidermal growth factor
receptor (HER)2 status. In terms of toxicity, febrile neutro-
penia and asthenia were the main side effects of TAC.
Shortly after the BCIRG-001 trial was reported, another
French study, the Federation Nationale des Centres de Lutte
Contre le Cancer PACS-01 trial [21], noted similar results
supporting the use of sequential docetaxel in early breast
cancer. Node-positive breast cancer patients were assigned
to receive FEC (fluorouracil 500 mg/m2, epirubicin 100 mg/m2,
and cyclophosphamide 500 mg/m2) for six cycles or the
same regimen of FEC for three cycles followed by docetaxel
100 mg/m2 every 3 weeks for another three cycles. The
multivariate analysis adjusting for prognostic factors identified
a statistically significant reduction in the relative risk for
relapse with FEC plus docetaxel (18%). There was a statis-
tically significant reduction in risk for death as well (27%).
The Eastern Cooperative Oncology Group 2197 trial [22]
randomized both node-positive and high-risk node-negative
breast cancer patients to receive four cycles of AC or four
cycles of AD (doxorubicin 60 mg/m2 plus docetaxel 60 mg/m2).
Recently communicated results, with a median of 79.5
months of follow up, revealed no differences in DFS or OS.
These negative results suggest either that the low dose of
docetaxel used in the combination (60 mg/m2) or that the
concurrent administration in a short course of AC are not the
most effective ways to use docetaxel in the adjuvant setting.
The US Oncology Network (USO) 9735 trial [23,24] is
unique because it compared four cycles of AC versus four
cycles of a taxane-containing, non-anthracycline regimen
(docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2
[TC]). Both node-positive and node-negative patients were
included in the trial. Both DFS and OS were statistically
significantly improved with TC. However, TC produced more
myalgia, arthralgia, edema and febrile neutropenia, whereas
more nausea and vomiting as well as one incident of
congestive heart failure were the main secondary effects in
the AC arm. In addition, TC was well tolerated in older
women, without excessive toxicity in comparison with their
younger counterparts.
The Breast International Group 02-98 trial [25] compared
four treatment arms: a sequential control (four cycles of
doxorubicin at 75 mg/m2, followed by three cycles of CMF); a
concurrent control arm (four cycles of doxorubicin at
60 mg/m2 plus cyclophosphamide at 600 mg/m2, followed by
three cycles of CMF); a sequential docetaxel arm (three
cycles of doxorubicin at 75 mg/m2, followed by three cycles
of docetaxel at 100 mg/m2, followed by three cycles of CMF);
and a concurrent docetaxel arm (four cycles of doxorubicin at
50 mg/m2 plus docetaxel at 75 mg/m2 followed by three
cycles of CMF). The analysis was performed after a median
follow up of at least 5 years but with less than two-thirds of
the number of DFS events originally planned, which limited
the statistical power to answer definitively the originally
planned questions. The primary comparison evaluated the
incorporation of docetaxel, regardless of its schedule of
administration, into anthracycline-based adjuvant chemo-
therapy, and it resulted in improved DFS of borderline
statistical significance (hazard ratio [HR] of a DFS event of
0.86). Secondary comparisons found differences in efficacy
possibly related to schedule of administration of chemo-
therapy. Thus, DFS was significantly better in the sequential
docetaxel arm than in the sequential control arm (HR of a
DFS event was 0.79), but DFS was no different in the
concurrent docetaxel arm and in the concurrent control (HR
of a DFS event was 0.93). When the two docetaxel arms
were compared, DFS was better in the sequential docetaxel
arm (HR of a DFS event was 0.83).
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patients were randomly assigned either to epirubicin
(120 mg/m2) for four cycles followed by CMF for four cycles
(considered the standard treatment in Italy during the late
1990s) or to sequential docetaxel (100 mg/m2) for four
cycles after four cycles of epirubicin and before four cycles of
CMF. With a median follow-up period of 53.6 months, there
was a tendency toward a benefit for the docetaxel-containing
arm in terms of DFS (21% reduction in the risk for relapse,
which was of borderline statistical significance).
The Taxotere as Adjuvant Chemotherapy trial [27] is the
largest first-generation taxane-based adjuvant trial conducted
to date. It compared four cycles of FE60C (fluorouracil
600 mg/m2, epirubicin 60 mg/m2, and cyclophosphamide
600 mg/m2 every 3 weeks) followed by four cycles of
docetaxel (100 mg/m2) versus a standard treatment (either
eight cycles of FE60C or four cycles of epirubicin 100 mg/m2
followed by four cycles of CMF, at investigators’ discretion).
No differences in DFS or OS between experimental and
standard arms were observed.
The Taxotere as Adjuvant Chemotherapy trial included both
node-positive and high-risk node-negative patients, but the
GEICAM 9805 trial [28] is the first taxane-based study that
exclusively enrolled women with node-negative early-stage
breast cancer at high risk for recurrence. As a complementary
study to that conducted by BCIRG 001, GEICAM 9805
tested the same treatment arms but in a different population.
TAC produced significantly more hematologic toxicity than
did FAC, although primary prophylaxis with granulocyte
colony-stimulating factor reduced the rate of neutropenic
fever. A significant improvement in 5-year DFS was demon-
strated in the TAC over the FAC arm, with 91% and 86%
patients, respectively, alive and disease free. The OS data,
although still immature, showed a nonsignificant 5-year OS of
97% for TAC and 95% for FAC.
Mavroudis and coworkers [29], from the Hellenic Oncology
Research Group, presented data from another phase III study
that compared the sequential administration of docetaxel (four
cycles of 100 mg/m2) followed by EC versus FE75C (fluorour-
acil 700 mg/m2, epirubicin 75 mg/m2, and cyclophosphamide
700 mg/m2 every 3 weeks) as adjuvant chemotherapy in
node-positive breast cancer. The docetaxel-containing treat-
ment significantly improved the recurrence-free survival, but it
was more toxic than FEC. The West German Study Group
has also reported the results of the randomized intergroup
phase III trial comparing EC followed by docetaxel versus
FE100C (fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and
cyclophosphamide 500 mg/m2 every 3 weeks) in patients with
intermediate-risk breast cancer. The 5-year OS rate was
significantly higher with EC followed by docetaxel (95%) than
for FEC (92.6%), suggesting the consideration of the
sequential regimen in patients with one to three involved
lymph nodes, even in hormone receptor-positive disease [30].
Second-generation taxane trials
Once the results of the first-generation taxane trials became
available, taxanes were adopted as the new standard adju-
vant treatment for node-positive breast cancer. Therefore, a
second generation of trials was planned to define further the
best taxane, the optimal schedule of administration, and
whether the addition of further agents might be of some
benefit. The trials discussed here are summarized in Table 3.
The earliest of these second-generation trials was the
CALBG 9741 trial [31]. It was designed to test two hypo-
theses: the first was that dose-dense administration of
chemotherapy was superior to conventional, every 3 weeks
administration; and the second was that sequential, full-drug
dosage was superior to combination chemotherapy. Node-
positive breast cancer patients were assigned to one of the
four possible treatment arms, consisting of sequential chemo-
therapy using doxorubicin, cyclophosphamide and paclitaxel,
or concurrent doxorubicin and cyclophosphamide followed by
paclitaxel at 14-day (with growth factor support) versus 21-
day intervals in a 2 × 2 factorial design. Dose-dense chemo-
therapy was superior to conventional scheduling, but there
was no significant difference between sequential and con-
current administration schedules. These data were consistent
with one of the underlying hypotheses (namely that dose
density could increase efficacy with a reasonable toxicity
profile) but not the other (that sequential, full-dose therapy is
superior to combination chemotherapy).
Other second-generation initiatives helped to shed light on the
best taxane and the best schedule of administration of taxanes
as well. The Southwest Oncology Group/Eastern Cooperative
Oncology Group E1199 trial [32] included 4,950 node-
positive or high-risk node-negative early breast cancer patients
and randomly assigned them to one of the four treatment arms
in a factorial design. All patients received AC for four cycles
followed by taxane treatment, either docetaxel or paclitaxel, for
12 weeks in a weekly schedule (80 mg/m2 paclitaxel and
35 mg/m2 docetaxel) or every 3 weeks for four cycles
(175 mg/m2 paclitaxel and 100 mg/m2 docetaxel). The primary
end-points of the study were docetaxel versus paclitaxel
efficacy and weekly versus every 3 weeks schedule. No
significant differences in efficacy were found in the primary
analysis (paclitaxel versus docetaxel, and weekly versus every
3 weeks schedule). This appears to have been due to the fact
that paclitaxel performed better weekly, whereas docetaxel
was more efficacious when administered every 3 weeks. As a
secondary analysis, there was significantly better DFS in the
group receiving weekly paclitaxel and in the group receiving
docetaxel every 3 weeks, as compared with the group
receiving paclitaxel every 3 weeks (considered as standard).
Besides the last two trials discussed above, the results from
the Cancer Research UK tAnGo phase III study [33] were
recently presented. This is the first trial to test whether the
addition of further chemotherapy agents to anthracycline and
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.taxane-containing regimens could be useful in the adjuvant
setting. tAnGo compared EC-GP (four cycles of epirubicin
90 mg/m2 and cyclophosphamide 600 mg/m2 every 3 weeks,
followed by four cycles of paclitaxel 175 mg/m2 on day 1 and
gemcitabine 1,250 mg/m2 on days 1 and 8 every 3 weeks)
versus four cycles of EC followed by four cycles of paclitaxel
175 mg/m2. No significant differences in DFS or OS were
observed between treatments.
At the 31st San Antonio Breast Cancer Symposium, data on
two clinical trials exploring different combinations of taxanes
were also reported. The NSABP B-30 [34] compared three
different regimens containing doxorubicin, docetaxel, and
cyclophosphamide in women with operable, node-positive
breast cancer (four cycles of AC followed by four cycles of
docetaxel; four cycles of AD; and four cycles of TAC).
According to the primary end-point, AC followed by docetaxel
was marginally superior to four cycles of TAC (HR = 0.86;
P = 0.086) and superior to four cycles of AD (HR = 0.83;
P = 0.034) in terms of OS. Also, AC followed by docetaxel
was superior to four cycles of TAC (HR = 0.83; P = 0.006)
and of AD (HR = 0.80; P = 0.001) in terms of DFS. Further-
more, there were no treatment interactions between baseline
nodal, estrogen receptor (ER), or menopausal status and
outcome. The main efficacy analysis of BCIRG 005 [35] was
also presented. This phase III randomized trial compared TAC
versus AC followed by docetaxel in women with normal
HER2 and axillary lymph node-positive early breast cancer. In
terms of the primary end-point, namely DFS, adjuvant TAC
was equivalent to AC followed by docetaxel, despite the
higher dose intensity of each of the three agents in the latter
regimen and the eight cycles of treatment. From the toxicity
standpoint, TAC was associated with more febrile
neutropenia and granulocyte colony-stimulating factor use
and less sensory neuropathy, nail change, and myalgia.
Interesting data from other taxane clinical trials are about to
be released (Table 4), and they are expected to provide
information on many unresolved issues in the field of taxane
chemotherapy, such as the following: the optimal adminis-
tration schedule and the optimal combination regimen
(NSABP B-38, USO 01062 and 11271, CALBG-40101,
Southwest Oncology Group 0221, GEICAM 2003-02 or
CT/01-04); the best taxane (NSABP B-38 and CT/04.22);
and the benefits of combination with other agents in the
adjuvant setting (NO17629, GEICAM 2003-10, and NSABP
B-38). Another major objective is to define the role of
anthracyclines in the adjuvant treatment of HER2-negative
patients. The USO Network 06090 trial is intended to
address this by comparing the TC and TAC regimens in more
than 2,000 early-stage breast cancer patients.
Systematic reviews and meta-analysis of taxanes
The magnitude of the benefit from including taxanes in the
adjuvant treatment of early breast cancer has been investi-
gated in several meta-analyses.
A pooled analysis including 15,500 patients, from nine trials
[14,15,17,20,21,23,36-38], was reported by Bria and co-
workers [39]. Significant differences in favor of taxanes were
seen in DFS in the overall population (relative risk [RR] =
0.86,  P < 0.00001) and lymph node-positive population
(RR = 0.84, P < 0.0001), and in OS in both populations
(RR = 0.87, P < 0.0001, and RR = 0.84, P < 0.0001, respec-
tively). The absolute benefits in DFS and OS in favor of
taxanes ranged from 3.3% to 4.6% and from 2.0% to 2.8%,
respectively. Even restricting the analysis to the lymph node-
positive patients, the absolute gains in DFS and OS were
4.3% and 2.8%, and the benefit was observed regardless of
whether the sequential or concomitant approach was
investigated. The number of patients needed to treat for a
single beneficial patient ranged from 23 to 31 for DFS and
from 36 to 50 for OS.
Subsequently, and with more mature survival data available,
the Cochrane Collaboration [40] selected 12 studies [14-17,
20,21,23,25,26,37,38,41], including more than 18,000
women and a median follow-up of 60.4 months. The HR was
0.81 (P < 0.00001) both for DFS and OS favoring taxane
regimens, with no statistical heterogeneity for either survival
end-point. This review was not able to identify a subgroup of
patients who benefit more or less from taxanes, and no
conclusions were drawn with respect to dosage and
scheduling.
Taxane-containing adjuvant trials were included in the most
recent, 2005 to 2006 updated version of the Early Breast
Cancer Trialists’ Collaborative Group overview presented
by Peto [9]. The recurrence rate ratio of taxane versus
anthracycline in 20,000 randomized women was 0.83
(2P < 0.00001). Stratifying women by age, in young women
the recurrence rate ratio of taxane versus no taxane was
0.38 (2P < 0.00001) and the breast cancer mortality rate
ratio was 0.46 (2P < 0.00001), whereas in older women
the proportional risk reduction was 0.52 (2P < 0.00001) in
terms of recurrence rate and 0.66 (P = 0.00002) in terms of
mortality. These data emphasize the role played by taxanes
as new drugs to be included in the adjuvant treatment
strategy of early breast cancer.
The largest meta-analysis reported thus far is that conducted
by De Laurentiis and coworkers [42]. It included 13 studies
[14-17,20,21,25,26,36-38,43,44] and as many as 22,903
patients. The pooled HR estimated was 0.83 (P < 0.00001)
for DFS and 0.85 (P < 0.00001) for OS. Risk reduction was
not influenced by the type of taxane (paclitaxel: HR = 0.83,
P = 0.0004; and docetaxel: HR = 0.87, P = 0.003), by ER
expression (ER-positive: HR = 0.83, P < 0.00001; and ER-
negative: HR = 0.79; P < 0.00001), by the number of axillary
metastases (one to three nodes: HR = 0.71, P < 0.0001; and
four nodes or more: HR = 0.75, P = 0.0001), or by age/
menopausal status. Taxane administration resulted in abso-
lute improvements in 5-year DFS/OS of 5% and 3%,
Breast Cancer Research    Vol 11 No 2 López-Tarruella and Martín
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(page number not for citation purposes)respectively, which is comparable to the reduction obtained
with anthracyclines and reported in the Early Breast Cancer
Trialists’ Collaborative Group meta-analysis [8], which
established taxanes’ gold-standard status in the adjuvant
setting.
Selection of candidates for adjuvant
chemotherapy
The identification of patients who do not need or are unlikely
to benefit from adjuvant chemotherapy is currently a relevant
problem, because small, node-negative tumors are the usual
form of presentation of the disease in the era of mammo-
graphic screening. Furthermore, there is also probably a
relevant subset of patients with node-positive breast cancer
(particularly those with high expression of ER) that does not
benefit from any chemotherapy [45]. However, the lack of
prospective validation of this concept in the setting of an
appropriate clinical trial renders its clinical application difficult.
In node-negative patients, tumor size, hormone receptor
status, lymphovascular invasion, and histologic and nuclear
grade have traditionally been the discriminating factors for
selecting node-negative breast cancer patients for adjuvant
chemotherapy. Adjuvant! [46], a program that estimates a
patient’s risk for recurrence with different therapeutic options
based on classical clinical and pathological findings, is often
used for the same purpose [47]. Patients with a risk for
relapse exceeding 10% (with or without hormonal therapy,
depending on hormone receptor status) are often offered
adjuvant chemotherapy. The St Gallen Consensus Confer-
ence [48] has also established successive classifications of
risk for relapse based on clinical and pathologic features,
including HER2 status in its last version. More recently, two
genomic signatures, Oncotype Dx® (Genomic Health Inc.,
Redwood City, CA, USA) and Mammaprint® (Agendia BV,
Amsterdam, The Netherlands), have been developed to
select those patients with node-negative disease who are
Available online http://breast-cancer-research.com/content/11/2/204
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Table 4
Overview of the main ongoing or closed but still not reported clinical trials that involve taxanes
Trial ID Design Patient characteristics and end-points
Trials not recruiting or completed
NO17629 AC×4→D100×4 versus AC×4→D75X×4 1,810 node-positive and high-risk node-negative patients
NSABP B-38 ACD×6 versus AC×4 (q2w)→P×4 (q2w)  4,800 node-positive patients; DFS (primary); OS, recurrence and 
versus AC×4 (q2w)→PG×4 (q2w) distant recurrence-free interval and toxicity (secondary)
CT/04.22 FEC×4 (q2w)→D×4 (q2w) versus  478 node-positive patients; DFS (primary); OS, recurrence rate, 
FEC×4 (q2w)→P×4 (q2w) toxicity and QoL (secondary) 
GEICAM 2003-10 EC×4→D×4 versus ED×4→X×4 1,382 node-positive patients; DFS (primary); OS, toxicity, QoL, SNP 
predictors and molecular markers (secondary)
GEICAM 2003-02 FAC×6 versus FAC×4→P×8w 1,920 high risk node-negative patients; DFS (primary); OS, toxicity, 
QoL and prognostic gene profile (2)
Trials actively recruiting
CALGB-40101 AC×4 (q2w) versus AC×6 (q2w)  4,646 with 0 to 3 positive nodes patients; DFS (primary); OS, local 
versus P×4 (q2w) versus P×6 (q2w) control, time to distant metastasis, toxicity, amenorrhea, MDR1 
haplotype effect, CYP polymorphism effect
LMU-ADEBAR EF (d1, d8) C (oral d1-14)×6 (q4w)  446 node-positive patients; time to progression (primary); OS, toxicity 
versus EC (d1, d21, d42, d63)→D (d84,  and QoL (secondary)
d105, d126,147)
SWOG-S0221 AC×6 (q2w)→P×6 (q2w) versus  4,500 node-positive and high-risk node-negative patients; DFS 
AC×6 (q2w)→P×12(w) versus  (primary); OS, toxicity and prognostic markers (secondary)
AC×15 (Aw, C oral d1-7)→P×6 (q2w) 
versus AC×15 (Aw, C oral d1-7)→P×12(w)
CT/01.04 D75×4→E90×4 versus E75D75×6 724 high-risk node-negative patients; DF interval (primary); OS and 
safety (secondary)
USO 06090 TAC×6 versus TC×6 HER2 negative and node-positive and high-risk node-negative patients; 
DFS (primary)
Overview of the main ongoing or closed but still unreported clinical trials that involve taxanes in their design as early breast cancer adjuvant
treatment. The first part of the table includes trials that are active but not recruiting or have already completed, and the second part of the table is
composed of clinical trials with active recruitment on August 2008, according to the National Cancer Institute Clinical Trial Database [71]. A,
doxorubicin; C, cyclophosphamide; D, docetaxel; DFS, disease-free survival; E, epirubicin; F, 5-fluorouracil; G, gemcitabine; OS, overall survival; P,
paclitaxel; QoL, quality of life; w, weeks; X, capecitabine.more likely to benefit from adjuvant chemotherapy. A detailed
description of these tools is beyond the scope of this over-
view. Pending a final validation in the MINDACT (Microarray
in Node Negative Disease May Avoid ChemoTherapy) and
TAILORx (Trial Assigning IndividuaLized Options for
Treatment [Rx]) trials [49,50], the genomic fingerprints
appear to predict recurrence in node-negative breast cancer
patients (and perhaps in node-positive patients as well) more
accurately than Adjuvant! or the classical prognostic factors.
Selection of adjuvant chemotherapy
Most adjuvant chemotherapy trials were performed in un-
selected patient populations or, more precisely, in popula-
tions selected according exclusively to anatomy (axillary
status) or demographics (menopausal status) rather than
tumor biology. Most of these trials did not stratify patients
according to hormonal status, even though the relevance of
this biologic factor was well known at the time when the trials
were designed. This lack of forward thinking is unfortunate.
We know that, overall, the taxane containing combinations
are superior to anthracycline (nontaxane) containing combi-
nations, and that the anthracyclines performed better than
CMF. In general, however, this superiority is associated with
more toxicity. Furthermore, the benefit of the newer combi-
nations over the older ones is small (3% to 5% in absolute
terms), and we cannot identify the subsets of patients who
actually benefit from the new drugs. In other words, we need
to treat 100 patients to benefit only three to five of them,
while administering what is usually a more toxic treatment to
the remaining 95 to 98 patients who do not derive any
survival benefit.
Several attempts have been made to identify the population
that actually benefits from anthracyclines versus CMF and
taxanes versus anthracyclines, but all of them are based on
retrospective subset analyses and meta-analyses.
Anthracyclines were considered the gold standard of adju-
vant chemotherapy until the late 1990s. In absolute terms, the
absolute DFS benefit conferred by anthracyclines compared
with CMF is about 3% at 5 years and 4% at 10 years in meta-
analyses [8,9], although one can speculate that the benefit
with anthracyclines is underestimated by the meta-analyses
because of the inclusion of ‘unfair’ trials with asymmetric
design (in particular, two large NSABP trials in which six
cycles of CMF were compared with four cycles of AC, which
identified no differences in outcome). However, the long-term,
sometimes fatal side effects of anthracyclines, in particular
cardiac toxicity and leukemias/myelodysplastic syndrome,
can partly counter-balance these benefits. Anthracyclines can
trigger a chronic, usually irreversible, dose-dependent cardio-
myopathy (type I) by causing myocardial structural changes
and cardiac tissue remodeling, the consequences of which
may appear months or years after chemotherapy. Although a
well recognized phenomenon, the real magnitude of the
problem of severe anthracycline-induced cardiac toxicity is
still a matter of debate. In randomized phase III clinical trials,
the prevalence of grade 2 to 4 cardiac toxicity with anthra-
cyclines was in the range 0.5% to 1.5 %, although the follow
up of these trials was less than 6 years. In the long term,
anthracycline-induced cardiac damage could have relevant
consequences, according to two population-based studies
conducted in older patients [51,52]. The cardiac toxicity of
anthracyclines is increased when these drugs are followed by
trastuzumab. In the trastuzumab adjuvant trials, the incidence
of severe cardiac toxicity with anthracyclines followed by
trastuzumab ranged from around 2% to 4% [53,54]. Apart
from cardiotoxicity, anthracyclines have other important long-
term adverse effects, such as acute myeloid leukemia and
myelodysplastic syndrome, which occur in around 0.5% of
patients [55,56].
Anthracycline use can be optimized in two ways: by selecting
patients who are more likely to benefit from these drugs
according to tumor biology, and by reducing the risk for
irreversible side effects. The latter could be attempted by
diminishing the total cumulative dose, selecting patients at
very low cardiac risk (young women without cardiac risks), or
introducing the newer liposomal formulations, which are
clearly less cardiotoxic.
The selection of patients whose tumors are more likely to
respond to anthracyclines is a field of currently intense
investigation. Several retrospective analysis and a meta-
analysis [57-59] have suggested that the improvement in
DFS and OS with adjuvant anthracyclines over CMF in the
phase III trials is restricted to patients whose tumors present
with the HER2 alteration. Other similar studies, however,
have found that the patients who actually benefit from
adjuvant anthracyclines are those whose tumors have topo-
isomerase II α amplification [58,60]. A plausible explanation
for this discrepancy is that most if not all topoisomerase II α
amplifications are observed in tumors with concurrent HER2
amplification [54]. Therefore, topoisomerase II α amplification
and not HER2 amplification would be the real predictive
factor. Regardless, the demonstration that the adjuvant
administration of the new targeted anti-HER2 monoclonal
antibody trastuzumab significantly improves DFS and OS in
breast cancer patients whose tumors over-express HER2
[54,61-64] will probably change the role of anthracyclines in
the adjuvant setting.
Anthracyclines appear to be most effective in patients whose
tumors have topoisomerase II α amplification (usually asso-
ciated with HER2 amplification), and we now have newer,
less toxic drugs that effectively target HER2-amplified tumors;
the role of anthracyclines should therefore be revisited.
Interestingly, support for this idea comes from the BCIRG
006 trial [54], which compared AC followed by docetaxel
versus this same regimen plus trastuzumab and the non-
anthracycline-containing combination THC (docetaxel, carbo-
platin, and trastuzumab) as adjuvant therapy for operable
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.breast tumors over-expressing HER2. A subgroup analysis
showed that AC followed by docetaxel plus trastuzumab was
not superior to THC in either subgroup of patients
(topoisomerase II α amplified and nonamplified tumors).
Statistically significant superiority of the two trastuzumab-
containing arms over AC followed by docetaxel was observed
in the group of patients whose tumors had amplification of
HER2 but not of topoisomerase II α. In the subgroup of
patients whose tumors had co-amplification of both genes,
the three arms were similarly effective. If these data are
maintained over time, then the role of anthracyclines in the
adjuvant setting would be seriously challenged, because
THC could be concluded to be similarly effective and is
clearly less cardiotoxic than the anthracycline-containing
combinations.
Regarding the taxanes, several attempts have been made to
discover molecular factors that could predict response to
these drugs. Unfortunately, none of the first-generation adju-
vant taxane trials were designed to determine the effective-
ness of taxanes in subgroups of patients with different tumor
biomarkers, with only retrospective, unplanned analyses
being available.
Berry and coworkers [65] reported the results of a combined
analysis of the CALGB/Intergroup experience, suggesting
that the benefit in favor of the most active chemotherapy
regimens, in particular those containing paclitaxel, over the
less aggressive ones is mostly limited to patients with ER-
negative breast cancer. Conversely, the pooled analysis of
BCIRG 001 and PACS-01 reported by Andre and coworkers
[66] did not identify any different effect on risk for recurrence
or death in ER-positive or ER-negative patients treated with
adjuvant docetaxel. The discrepancy in results of the same
subset analysis is also present in two trials with very similar
design (CALGB-9344 [14] and NSABP B-28 [15]), which
compared AC versus AC followed by paclitaxel, and this
clearly highlights the caution we should exercise when look-
ing at the results of unplanned subset analyses. Furthermore,
the results of other trials such as GEICAM 9906 [16] do not
support Berry’s suggestion. A specific review [67] and the
taxane meta-analysis data do not support the view that the
efficacy of taxanes is significantly related to hormone receptor
status. In particular, De Laurentiis and coworkers [42] were
able to show that taxanes significantly reduced the risk for
recurrence, irrespective of ER status (ER positive: HR = 0.83,
P < 0.00001; and ER negative: HR = 0.79, P < 0.00001),
and that the magnitude of the relative benefit was almost
constant across subgroups (Table 5).
The relationship between HER2 status and taxane efficacy
has been explored in a few studies, which yielded conflicting
conclusions. Hayes and coworkers, using tumor samples
from patients of the CALBG-9344 trial [68], tried to
determine whether HER2 expression identified patients who
were likely to benefit from doses of doxorubicin above
60 mg/m2, the addition of paclitaxel after anthracyclines, or
both. There was an interaction between HER2 positivity and
benefit from paclitaxel addition, with an HR for recurrence of
0.59 (P = 0.01) regardless of ER status. However, these
results were not confirmed by the GEICAM 9906 trial [16], in
which no significant interaction was found between treatment
with paclitaxel and HER2 status.
Other molecular markers that are more or less related to the
mechanism of action or metabolism of taxanes (such as
β-tubulin isotypes, protein tau, P-glycoprotein, and so on) and
some genetic signatures have been proposed as predictors
of taxane efficacy [69,70]. These studies have a reduced
power to detect clinically meaningful relationship because of
the limited sample size and other methodological problems.
None of these markers have been validated by large
prospective clinical trials or meta-analysis, and therefore we
are presently unable to select patients who may benefit from
adjuvant taxanes based on molecular features.
Conclusions
Taxanes and trastuzumab have permanently entered the
adjuvant setting, based on their consistently positive results
in randomized clinical trials. The discussion of which is the
best regimen or schedule, and new strategies to combine all
of these tools is wide open. However, these new alternatives
have challenged the established role of anthracyclines as the
backbone of adjuvant treatment in early breast cancer. With a
growing pool of active drugs, their tolerability and - more
importantly - their long-term toxicity profiles come into focus
when considerations turn to cure and preservation of quality
of life.
A whole spectrum of targeted drugs is being or is about to be
tested for use in early breast cancer, once they have demon-
strated activity in advanced stages of the disease. Their ability
to interfere with survival, proliferation, and angiogenesis or
the motility, migration, and invasiveness processes of tumor
cells could be even more relevant in this earlier phase of the
natural history of breast cancer.
As the number of treatment options increases, the need to
define a set of criteria to select those patients who will
benefit from each treatment regimen or strategy becomes a
priority. The appropriateness of clinical trial designs to
address this issue is currently a major concern.
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